Filing Analysis
Imunon, Inc. announced that its Compensation Committee approved new compensatory programs allowing certain executive officers to elect to receive a portion of their base salary in common stock.
🚩 Red Flags
- Potential dilution via executive equity compensation elections.
📋 Key Facts
- Stacy Lindborg (CEO) may elect up to 50% of her base salary in shares; includes additional shares issuable through September 25, 2026.
- Michael Tardugno (Executive Chairman) may elect up to 100% of his base salary in shares; includes additional shares issuable through September 25, 2026.
- Douglas Faller (CMO) may elect up to 40% of his base salary in shares; includes additional shares issuable through September 25, 2026.
- The stock elections for the CEO and Executive Chairman are deemed exempt from registration under Section 4(a)(2) of the Securities Act.
Imunon, Inc. announced the retirement of interim CFO Jeffrey Church effective July 1, 2026, and the appointment of Josh Blacher as new interim CFO via a master services agreement with Danforth Health, Inc.
🚩 Red Flags
- Use of interim/consultant CFOs often indicates instability in permanent leadership or cash flow constraints preventing full-time hires.
- Reliance on hourly consulting rates ($475/hr) for a principal officer role can lead to high, variable professional service costs.
📋 Key Facts
- Jeffrey Church is retiring from his role as interim CFO on July 1, 2026; he will remain as a consultant with a $10,000 monthly retainer.
- Josh Blacher appointed as new interim CFO effective July 1, 2026.
- Blacher's services are provided through Danforth Health, Inc. at an hourly rate of $475.
- The company is utilizing a third-party financial advisory firm (Danforth) to provide the interim CFO.
Imunon, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 16, 2026. Key outcomes included the election of Class I directors, ratification of the independent auditor, and approval of an amendment to the 2018 Stock Incentive Plan.
📋 Key Facts
- Stockholders approved an increase of 1,000,000 shares to the 2018 Stock Incentive Plan, bringing the new aggregate limit to 1,265,004 shares.
- Mr. Frederick J. Fritz and Ms. Christine A. Pellizzari were elected as Class I directors until 2029.
- WithumSmith + Brown, PC was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- The 2025 executive compensation ('Say-on-Pay') was approved on an advisory basis.
- A quorum was established with 1,808,666 shares represented out of 3,983,342 outstanding shares.
Imunon, Inc. entered into a complex $10 million financing arrangement with Streeterville Capital, LLC involving the issuance of Series A Preferred Stock and two secured promissory notes. While the company received $10 million in cash, 50% of these proceeds are immediately restricted as collateral for the debt.
🚩 Red Flags
- High collateralization: 50% of the funding is restricted in a collateral account, limiting immediate liquidity.
- Aggressive security: The notes are secured by 'substantially all of the assets of the Company', creating significant risk of asset loss upon default.
- Restrictive redemption: Investor can redeem principal of Note A-1 monthly starting in six months, and can redeem additional amounts based on trading volume.
- Default penalties: Interest rates jump to 15% upon an event of default.
- Multiple 8-K items: Filing covers items 1.01, 2.03, 3.02, 5.03, 7.01, and 9.01.
📋 Key Facts
- Total transaction value: $10,000,000 closed on June 3, 2026.
- Capital structure: 250 shares of Series A Preferred Stock ($2.5M), Secured Promissory Note A-1 ($2.72M), and Secured Promissory Note B ($5.0M).
- Collateral: $5,000,000 of the proceeds are held in a Cash Collateral Account; Notes are secured by substantially all assets except intellectual property.
- Interest rates: Note A-1 at 8% per annum; Note B at 5% per annum; both mature in 18 months.
- Preferred Stock: 8% annual return, non-convertible, with a stated value of $12,000 per share.
- Fees: Company paid a 7.0% placement agent fee on gross proceeds.
Imunon, Inc. reported its financial results for the first quarter ended March 31, 2026, and hosted a conference call to provide a business update.
📋 Key Facts
- The company issued a press release on May 12, 2026, regarding Q1 2026 financial results.
- A conference call and live internet broadcast were scheduled for May 12, 2026.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- Financial results cover the quarter ended March 31, 2026.
Imunon, Inc. has entered into Change in Control (CIC) agreements with its top executive team, including the CEO, CMO, and General Counsel. These agreements provide for significant cash severance and full equity acceleration in the event of termination following a change in corporate control.
🚩 Red Flags
- Implementation of 'Golden Parachute' provisions for the entire C-suite simultaneously can indicate an impending sale or change in control.
- Significant cash outflows and equity dilution could occur upon a change in control, potentially impacting the net value to shareholders in an acquisition.
📋 Key Facts
- Agreements were entered into on May 1, 2026, with CEO Stacy Lindborg, CMO Douglas Faller, and GC Susan Eylward.
- CEO Stacy Lindborg is entitled to a lump sum payment of 2.5x the sum of her annual base salary and target bonus.
- Other executive officers (Faller and Eylward) are entitled to 1.5x their annual base salary and target bonus.
- The agreements include full acceleration of all outstanding equity awards and up to 24 months of health/life insurance premiums for the CEO (18 months for others).
- Benefits are triggered if the executive is terminated without cause or resigns for good reason within one year after or four months prior to a change in control.
Imunon, Inc. reported its financial results for the fiscal year ended December 31, 2025, and hosted a conference call to provide a business update. The filing serves as a routine disclosure of annual performance and management commentary.
📋 Key Facts
- Financial results reported for the fiscal year ended December 31, 2025.
- Press release issued and furnished as Exhibit 99.1 on March 31, 2026.
- Conference call and webcast held on March 31, 2026, at 11:00 AM ET.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
Imunon, Inc. has increased its At-the-Market (ATM) offering capacity by $7 million, bringing the total potential aggregate sales under its agreement with H.C. Wainwright & Co. to $17 million.
🚩 Red Flags
- Potential for shareholder dilution as the company expands its ability to sell shares directly into the market.
- Ongoing reliance on ATM offerings typically indicates a high cash burn rate and a lack of alternative financing for micro-cap companies.
📋 Key Facts
- Filed a prospectus supplement on March 23, 2026, to register an additional $7,000,000 in common stock.
- The total aggregate capacity of the ATM Sales Agreement is now $17,000,000, up from $10,000,000.
- As of the filing date, the company has already sold $4,797,848 of common stock under the existing agreement.
- H.C. Wainwright & Co., LLC is serving as the sales agent.
- The original Sales Agreement dates back to May 25, 2022, and was previously amended on May 15, 2024.
Imunon, Inc. announced the retirement of its Executive Vice President and Chief Scientific Officer, Khursheed Anwer, effective February 20, 2026. To facilitate a smooth transition, Dr. Anwer will move into a consulting role through December 31, 2026.
🚩 Red Flags
- Departure of a key scientific officer (CSO) can sometimes signal shifts in R&D direction or pipeline challenges, though no disagreement was noted here.
📋 Key Facts
- Khursheed Anwer is retiring as EVP and Chief Scientific Officer on February 20, 2026.
- The departure is stated to be without any disagreements with management.
- Dr. Anwer will serve as a consultant from Feb 20, 2026, until Dec 31, 2026.
- Consulting compensation includes a $10,000 monthly retainer.
- Severance package includes 12 months of base salary and COBRA coverage following the retirement date.
Imunon, Inc. announced the resignation of interim CFO Kimberly Graper effective January 14, 2026. To fill the vacancy, the company has appointed former CFO Jeffrey Church as interim CFO, principal financial officer, and principal accounting officer.
🚩 Red Flags
- High turnover in the CFO position (interim role being vacated)
- Reliance on an interim/retired executive to stabilize financial leadership
- Ongoing consulting arrangement with a former officer involving significant monthly retainers ($30,000/month)
📋 Key Facts
- Kimberly Graper is resigning as interim CFO on January 14, 2026, to pursue other opportunities.
- Jeffrey Church will assume the role of interim CFO, principal financial officer, and principal accounting officer effective January 14, 2026.
- Mr. Church previously served as EVP and CFO at Imunon until his retirement in May 2024.
- The company amended its consulting agreement with Mr. Church to include a $30,000 monthly retainer plus hourly fees for excess work.
Imunon, Inc. entered into a Securities Purchase Agreement for a registered direct offering of common stock and warrants to a single institutional investor. The offering is expected to raise approximately $7.0 million in gross proceeds.
🚩 Red Flags
- Significant dilution potential due to the large number of warrants (nearly 2 million) and pre-funded warrants being issued alongside common stock.
- Concentration risk: The offering is to a single healthcare-focused institutional investor.
- The inclusion of pre-funded warrants often indicates the company may have struggled to find investors willing to take immediate equity at full price or is managing cash runway via complex instruments.
📋 Key Facts
- Offering size: 330,000 shares of common stock plus pre-funded warrants (up to 1,609,114 shares) and warrants (up to 1,939,114 shares).
- Combined offering price: $3.61 per share/warrant for common stock/warrants; $3.6099 for pre-funded warrants.
- Warrant exercise price: $3.482 per share with a 5-year term.
- Gross proceeds expected: Approximately $7.0 million (before fees).
- Use of proceeds: General corporate purposes, R&D, capital expenditures, and working capital.
- Closing date: Expected on or about December 31, 2025.
- Lock-up period: Officers and directors are subject to a 60-day lock-up following closing.
Imunon, Inc. filed an 8-K to furnish its quarterly financial results for the period ended September 30, 2025. The filing serves as a formal announcement of the earnings release and accompanying conference call.
📋 Key Facts
- Reporting date: November 13, 2025
- Period covered: Quarter ended September 30, 2025
- The company held a conference call on November 13, 2025, to discuss financial results and provide a business update.
- Financial results were furnished via press release (Exhibit 99.1).
Imunon, Inc. has received notification from the Nasdaq Hearings Panel that it has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on the NASDAQ Capital Market.
🚩 Red Flags
- The company was previously in violation of Nasdaq's minimum bid price requirement, indicating past extreme volatility or significant share dilution/price depression.
📋 Key Facts
- Notification date: August 27, 2025
- Compliance achieved regarding Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Requirement)
- Company has successfully avoided immediate delisting by meeting the $1.00 minimum bid price standard.
Imunon, Inc. filed an 8-K to furnish its quarterly financial results and business update for the period ended June 30, 2025.
📋 Key Facts
- Reporting of financial results for the quarter ended June 30, 2025.
- The company held a conference call on August 5, 2025, to discuss results and provide a business update.
- Financial statements are provided via Exhibit 99.1 (Press Release).
Imunon, Inc. announced a 15% stock dividend approved by the Board of Directors. This is a non-cash distribution of additional shares to existing shareholders.
🚩 Red Flags
- While not a reverse split, stock dividends can sometimes be used to manipulate share price perception or adjust capital structure without changing fundamental value.
📋 Key Facts
- Board approved a 15% stock dividend (0.15 shares for every 1 share held).
- Record date set for August 7, 2025.
- Payment date scheduled for August 21, 2025.
Imunon, Inc. has announced a 1-for-15 reverse stock split to be effective July 25, 2025. This move will reduce the company's outstanding common shares from approximately 31.8 million to 2.1 million.
🚩 Red Flags
- Reverse stock split (often used to maintain Nasdaq listing requirements by boosting share price).
- Significant reduction in float/outstanding shares.
📋 Key Facts
- Reverse stock split ratio: 1-for-15.
- Effective Date: July 25, 2025, at 12:01 a.m. Eastern Time.
- Pre-split shares: ~31.8 million; Post-split shares: ~2.1 million.
- The split will not change the authorized number of shares or par value.
- No fractional shares will be issued; stockholders with fractions will receive one full share instead.
Imunon, Inc. has filed a prospectus supplement to register an additional $4.5 million of common stock under its existing At the Market (ATM) offering agreement with H.C. Wainwright & Co., LLC. This increases the total aggregate amount registered under this Sales Agreement to $10,000,000.
🚩 Red Flags
- Continued use of At the Market (ATM) offerings often indicates a need for immediate liquidity and can lead to significant shareholder dilution.
- The increase in the registration amount suggests the company's previous $5.5M offering capacity was insufficient or used rapidly.
📋 Key Facts
- Filed a prospectus supplement on July 22, 2025, to register an additional $4,500,000 of common stock.
- The offering is conducted via an At the Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC.
- Total aggregate amount registered under the Sales Agreement is now increased to $10,000,000.
- Prior to this filing, the company had already sold 1,815,267 shares through the Sales Agent.
Imunon, Inc. has received a temporary exception from the Nasdaq Hearing Panel regarding its delisting status. The company is currently facing dual non-compliance issues: failure to maintain a $1.00 minimum bid price and failure to meet minimum stockholders' equity requirements.
🚩 Red Flags
- Delisting notice/determination letter received (May 28, 2025).
- Failure to meet Minimum Bid Price Requirement ($1.00).
- Failure to meet Minimum Stockholders' Equity Requirement.
- Ineligibility for standard 180-day extension due to low equity.
- Potential for a reverse stock split to regain compliance.
📋 Key Facts
- Nasdaq Hearing Panel granted an 'Exception' on July 11, 2025, providing time to regain compliance with Minimum Bid Price and Minimum Stockholders' Equity requirements.
- The company failed the $1.00 minimum bid price requirement for a period ending May 27, 2025.
- The company is in violation of Nasdaq Listing Rule 5550(b)(1) regarding minimum stockholders' equity.
- Stockholders approved an amendment to the 2018 Stock Incentive Plan on July 11, 2025, increasing the share limit by 2,000,000 shares (new total: 3,970,000 shares).
- The company is ineligible for a standard 180-day extension due to failing the $5M minimum stockholders' equity initial listing requirement.
Imunon, Inc. held its 2025 Annual Meeting of Stockholders where shareholders approved several significant measures, most notably a reverse stock split and a massive increase in authorized share count.
🚩 Red Flags
- Approval of a reverse stock split (ratio 1:5 to 1:18), typically used to maintain Nasdaq listing requirements or combat low share prices.
- Massive increase in authorized shares (from 112.5M to 350M) which facilitates significant future dilution.
📋 Key Facts
- Shareholders approved an amendment to increase authorized common stock from 112,500,000 to 350,000,000 shares (Proposal 5).
- Shareholders approved a reverse stock split with a ratio between 1:5 and 1:18 at the Board's discretion (Proposal 6).
- Ratification of WithumSmith + Brown, PC as independent auditors for FY2025 (Proposal 2).
- Approval of Nasdaq Rule 5635(d) compliance regarding share issuance underlying certain warrants (Proposal 4).
Imunon, Inc. has terminated its consulting agreement with Monomoy Advisors, LLC and the service of David Gaiero as interim Chief Financial Officer, effective June 13, 2025. Kimberly Graper, who joined the company in 2022, has been appointed as the new interim CFO, principal financial officer, and principal accounting officer.
🚩 Red Flags
- Frequent turnover in the interim CFO role (Gaiero served since June 2024; Graper takes over June 2025).
- Use of 'interim' leadership suggests potential instability or difficulty in recruiting permanent financial executives.
📋 Key Facts
- Effective date of changes: June 13, 2025.
- Termination of David Gaiero's service as interim CFO (held position since June 2024).
- Termination of consulting agreement with Monomoy Advisors, LLC.
- Kimberly Graper appointed as interim CFO, principal financial officer, and principal accounting officer.
- Ms. Graper's compensation includes a $244,800 base salary and a 30% target annual performance bonus.
Imunon, Inc. reports that it has regained compliance with Nasdaq's minimum bid price requirement after maintaining a closing price above $1.00 for 10 consecutive trading days. However, the company remains in violation of the minimum stockholders' equity requirement and is currently appealing a delisting determination via a Nasdaq Hearing Panel.
🚩 Red Flags
- Ongoing delisting risk due to non-compliance with minimum stockholders' equity requirements.
- Active litigation/hearing process pending with Nasdaq Hearing Panel regarding potential delisting.
- Low total stockholders' equity ($3.0M) relative to typical micro-cap operational needs.
📋 Key Facts
- Regained compliance with Nasdaq Minimum Bid Price Requirement ($1.00) as of June 6, 2025, after 10 consecutive trading days above the threshold.
- The company is currently in violation of the Minimum Stockholders' Equity Requirement (Nasdaq Listing Rule 5550(b)(1)).
- A delisting determination letter was received on May 28, 2025; a hearing request filed on May 29, 2025, has stayed the suspension of trading.
- Warrant holders exercised warrants on May 30 and June 2, 2025, providing $2.0 million in net proceeds.
- Total stockholders' equity as of May 31, 2025, is reported at $3.0 million.
Imunon, Inc. has received a delisting determination letter from Nasdaq due to failure to meet both the minimum bid price requirement and the minimum stockholders' equity requirement. The company intends to appeal via a hearing request to stay the suspension of trading.
🚩 Red Flags
- Delisting notice (Nasdaq)
- Failure to meet minimum stockholders' equity requirement
- Failure to maintain minimum bid price ($1.00)
- Potential for trading suspension on June 6, 2025
- Mention of potential reverse stock split as a remedial measure
📋 Key Facts
- Received Delisting Determination Letter on May 28, 2025.
- Failed to regain compliance with the $1.00 Minimum Bid Price Requirement by the May 27, 2025 deadline.
- Ineligible for a second 180-day extension because it failed to meet the $5,000,000 minimum stockholders' equity requirement (notified on May 19, 2025).
- Trading suspension is scheduled for June 6, 2025, unless a hearing request is filed by June 4, 2025.
- The company intends to request a hearing and may implement a reverse stock split to regain compliance.
Imunon, Inc. entered into a securities purchase agreement for a private placement of common stock and warrants to raise approximately $3.25 million in gross proceeds. The offering includes significant warrant coverage that could lead to substantial future dilution.
🚩 Red Flags
- Significant potential dilution: The total number of shares issuable via warrants (approx. 18.9M) is significantly higher than the initial shares sold (approx. 2.7M).
- Warrant overhang: Large volume of warrants could create downward pressure on stock price upon exercise/sale.
- Requirement for stockholder approval to issue certain warrants, indicating potential regulatory or exchange compliance hurdles.
📋 Key Facts
- Private placement of 2,777,779 shares of common stock at $0.45 per share (combined price with warrants).
- Issuance of pre-funded warrants to purchase up to 4,444,444 shares at $0.0001 exercise price.
- Issuance of warrants to purchase up to 14,444,446 shares at an exercise price of $0.45 per share.
- Aggregate gross proceeds from the initial placement: ~$3.25 million.
- Potential additional gross proceeds of ~$6.5 million if all warrants are exercised via cash exercise.
- H.C. Wainwright & Co., LLC acting as lead placement agent with a 7.0% cash fee plus expenses and warrants.
- Closing expected on or about May 27, 2025.
Imunon, Inc. has requested the SEC's consent to withdraw its Form S-1 Registration Statement, effectively canceling a planned public offering of securities.
🚩 Red Flags
- Abrupt cancellation of a public offering after multiple amendments suggests significant internal or market-driven issues regarding the feasibility of the raise.
- The withdrawal follows several rapid amendments (May 13, May 19), which often indicates difficulty in meeting SEC requirements or finding suitable investors.
📋 Key Facts
- The Company requested withdrawal of Registration Statement No. 333-286403 on May 22, 2025.
- The registration statement had been previously amended on May 13, 2025, and May 19, 2025.
- Imunon has officially determined not to pursue the public offering associated with this filing.
Imunon, Inc. received a deficiency notice from Nasdaq for failing to meet the minimum stockholders' equity requirement of $2,500,000 under Nasdaq Listing Rule 5550(b)(1). The company has until July 3, 2025, to submit a compliance plan.
🚩 Red Flags
- Delisting notice for failure to meet minimum stockholders' equity requirements.
- Cumulative regulatory risk: The company is already facing a separate deficiency regarding Nasdaq's minimum bid price requirement.
- Potential for delisting if compliance plans are rejected or not met within the extension period.
📋 Key Facts
- Received notice from Nasdaq on May 19, 2025, regarding non-compliance with Minimum Stockholders' Equity Requirement (Nasdaq Listing Rule 5550(b)(1)).
- The company does not meet the $2.5 million minimum equity threshold.
- Deadline to submit a plan to regain compliance is July 3, 2025 (45 days from notice).
- If a plan is accepted, Nasdaq may grant up to a 180-day extension to evidence compliance.
- The deficiency is separate from the previously disclosed minimum bid price requirement deficiency (filed Nov 27, 2024).
Imunon, Inc. entered into an agreement to exchange 5,000,000 warrant shares for 2,921,000 common stock shares. This transaction represents a significant issuance of equity, totaling 19.98% of the company's outstanding common stock.
🚩 Red Flags
- Significant dilution: The issuance of 2.92M shares represents nearly 20% of the total outstanding common stock.
- Potential for immediate selling pressure following the expiration of the lock-up period on May 14, 2025.
📋 Key Facts
- Agreement dated May 12, 2025, to exchange warrants issued on August 1, 2024.
- The Company will issue 2,921,000 shares of Common Stock in exchange for the Warrants.
- The issuance represents 19.98% of the total outstanding common stock as of the agreement date.
- Warrant Holders agreed to a lock-up period ending on May 14, 2025.
- Transaction is expected to close on May 13, 2025.
- The exchange is being conducted in reliance on Section 3(a)(9) of the Securities Act.
Imunon, Inc. filed an 8-K to furnish its quarterly financial results and business update for the period ended March 31, 2025. The filing serves as a formal announcement of the earnings release and associated conference call.
📋 Key Facts
- Reporting date: May 12, 2025
- Financial results reported are for the quarter ended March 31, 2025
- Company held/is holding a conference call on May 12, 2025, to discuss financial results and business updates
- The information is furnished under Item 2.02 and not 'filed' for purposes of Section 18 liability
Imunon, Inc. announced the finalization of its Phase 3 study design with the FDA for IMNN-001, intended to treat women with newly diagnosed advanced ovarian cancer. The company scheduled a conference call for March 25, 2025, to discuss the OVATION 3 trial.
📋 Key Facts
- FDA has finalized the Phase 3 study design for IMNN-001 (treatment for advanced ovarian cancer).
- The clinical trial is identified as the Phase 3 OVATION 3 trial.
- Company scheduled a conference call and webcast for March 25, 2025, at 2:00 p.m. ET to discuss the trial.
Imunon, Inc. filed an 8-K to furnish its press release announcing financial results for the fiscal year ended December 31, 2024. The filing serves as a formal announcement of the company's annual earnings and business update.
📋 Key Facts
- Reporting period: Fiscal year ended December 31, 2024.
- Report date: February 27, 2025.
- The filing includes a press release (Exhibit 99.1) containing financial results and a business update.
- A conference call was held on February 27, 2025, to discuss the results.
Imunon, Inc. announced the appointment of Dr. Douglas Faller as Chief Medical Officer, effective February 18, 2025. The appointment includes an inducement grant of 100,000 stock options to secure his employment.
🚩 Red Flags
- Inducement grant of 100,000 shares outside the existing stock incentive plan may indicate a need for high-level talent acquisition to drive clinical progress.
📋 Key Facts
- Dr. Douglas Faller appointed as Chief Medical Officer (CMO) on February 9, 2025.
- Effective date of employment is February 18, 2025.
- Base salary set at $480,000 with a targeted annual performance bonus of 40% ($192,000).
- Inducement grant: 100,000 shares of common stock options granted outside the 2018 Stock Incentive Plan.
- Options feature a 10-year term and a 4-year vesting schedule (25% cliff at year one).
- Dr. Faller brings extensive experience from Takeda Pharmaceuticals, Oryzon Genomics, and Skyhawk Therapeutics.
Imunon, Inc. received a deficiency notice from Nasdaq because its common stock bid price closed below the $1.00 minimum requirement for 30 consecutive business days. The company has an initial 180-day period to regain compliance.
🚩 Red Flags
- Delisting notice (non-compliance with minimum bid price requirement)
- Potential for delisting from Nasdaq Capital Market if compliance is not achieved by May 27, 2025
📋 Key Facts
- Received notification from Nasdaq staff on November 26, 2024.
- Deficiency is based on Nasdaq Listing Rule 5550(a)(2) regarding the $1.00 minimum bid price requirement.
- The company has an initial compliance period until May 27, 2025.
- To regain compliance, the stock must close at $1.00 or more for at least 10 consecutive business days before the deadline.
- A second 180-day compliance period may be available if certain conditions are met.
Imunon, Inc. filed an 8-K to furnish its third quarter 2024 financial results and provide a business update via press release. The filing serves as the formal mechanism to disclose quarterly earnings for the period ended September 30, 2024.
📋 Key Facts
- Reporting of financial results for the quarter ended September 30, 2024.
- The company held a conference call on November 7, 2024, to discuss results and business updates.
- Information was furnished pursuant to Item 2.02 of Form 8-K.
Imunon, Inc. announced the appointment of Susan Eylward as General Counsel and Corporate Secretary, effective October 7, 2024. The filing details her compensation package, including a base salary and an inducement stock option grant.
📋 Key Facts
- Susan Eylward appointed as General Counsel and Corporate Secretary on October 4, 2024.
- Employment effective date: October 7, 2024.
- Base salary: $340,000 per annum.
- Target annual performance bonus: 30% of base salary.
- Inducement grant: 50,000 shares of common stock via options with a 10-year term and 4-year vesting schedule (25% cliff at year one).
- The option grant is being issued outside the Company's 2018 Stock Incentive Plan per Nasdaq Listing Rule 5635(c)(4).
Imunon, Inc. is resuming its 'At the Market' (ATM) equity offering program by filing a new prospectus supplement to its existing S-3 registration statement. This follows a previous suspension of sales under the ATM Prospectus announced in July 2024.
🚩 Red Flags
- Resumption of ATM program often indicates a need for immediate liquidity to fund operations (common in micro-cap biotech).
📋 Key Facts
- Company is resuming sales of securities under an existing At the Market (ATM) Agreement with H.C. Wainwright & Co., LLC.
- A new prospectus supplement was filed on September 3, 2024, to support the resumption of sales.
- The company previously notified Wainwright on July 30, 2024, that it was suspending use of the ATM Prospectus.
- Legal opinion from Covington & Burling LLP was filed regarding the validity of the ATM Shares.
Imunon, Inc. filed an 8-K to furnish its second quarter 2024 financial results and provide a business update via press release. The filing is primarily a routine disclosure of quarterly earnings.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2024.
- Filing date: August 14, 2024.
- The company held/is holding a conference call on August 14, 2024, to discuss results and business updates.
- Information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 liability.
Imunon, Inc. filed a prospectus supplement to its existing S-3 registration statement for a registered direct offering of 5,000,000 shares of common stock.
🚩 Red Flags
- Potential dilution for existing shareholders due to the issuance of 5,000,000 new shares.
📋 Key Facts
- The company is conducting a registered direct offering under an effective Form S-3 (File No. 333-279425).
- Total number of shares to be issued: 5,000,000 shares of common stock.
- Filing includes a legal opinion from Covington & Burling LLP regarding the validity of the registered shares.
Imunon, Inc. announced a registered direct offering and concurrent private placement of 5 million shares of common stock and 5 million warrants at $2.00 per share. The company expects to raise approximately $10 million in gross proceeds for working capital and general corporate purposes.
🚩 Red Flags
- Significant dilution expected from the issuance of 5 million new shares and 5 million warrants.
- The company is terminating its existing 'at the market' (ATM) offering prospectus, suggesting a shift in financing strategy or exhaustion of previous methods.
- Heavy reliance on external capital for working capital suggests ongoing cash burn.
📋 Key Facts
- Offering size: 5,000,000 shares of Common Stock and 5,000,000 Warrants.
- Price per share/warrant: $2.00.
- Expected gross proceeds: $10.0 million (before fees).
- Warrant terms: Exercise price of $2.00; term of 5.5 years.
- Closing date: Expected on or about August 1, 2024.
- Placement agents: H.C. Wainwright & Co., LLC and Brookline Capital Markets.
- Lock-up period: Officers and directors are subject to a 30-day lock-up following closing.
Imunon, Inc. announced positive topline data from its Phase 2 OVATION 2 clinical trial of IMNN-001 for advanced ovarian cancer. The results showed improvements in both Overall Survival and Progression Free Survival across various patient subgroups.
🚩 Red Flags
- The clinical data, while showing improved median survival times, failed to reach statistical significance (pNS) in the primary and secondary endpoints for the Intent-to-Treat (ITT) population.
📋 Key Facts
- Announced positive topline data from the Phase 2 OVATION 2 trial of IMNN-001 combined with chemotherapy.
- Primary endpoint (Progression Free Survival) for ITT population: 14.9 months vs 11.9 months (HR 0.79).
- Secondary endpoint (Overall Survival) for ITT population: 40.5 months vs 29.4 months (HR 0.74).
- PARP treated patients showed significant PFS benefit: 33.8 months vs 22.1 months.
- All reported p-values were noted as 'pNS' (not statistically significant) despite favorable hazard ratios.
Imunon, Inc. reported the results of its 2024 Annual Meeting of Stockholders held on June 12, 2024. The meeting included elections for directors and ratification of the independent auditor.
📋 Key Facts
- Dr. Stacy R. Lindborg was elected to the Board of Directors until the 2027 Annual Meeting.
- James E. Dentzer was elected to the Board of Directors until the 2027 Annual Meeting.
- Stockholders ratified the appointment of WithumSmith + Brown, PC as the independent registered public accounting firm for fiscal year ending Dec 31, 2024.
- The 'Say-on-Pay' advisory vote regarding 2023 executive compensation was approved.
Imunon, Inc. announced the retirement of its CFO, Jeffrey Church, effective June 1, 2024, and the appointment of David Gaiero via a professional services agreement with Monomoy Advisors, LLC.
🚩 Red Flags
- Departure of a long-tenured CFO (since 2010) can signal internal instability or strategic shifts.
- Use of an interim/outsourced CFO via a consulting firm (Monomoy Advisors) rather than a full-time permanent hire often suggests the company is in a transitional or cost-saving phase.
📋 Key Facts
- Jeffrey Church (CFO since July 2010) to retire on June 1, 2024.
- Church will transition to a consulting role through December 31, 2024.
- Consulting terms for Church: $10,000 monthly retainer + $250/hour for work exceeding 40 hours/month.
- Church is entitled to a retirement bonus of $428,615.00 and eligibility for pro-rated 2023/2024 bonuses.
- David Gaiero appointed as new CFO via Monomoy Advisors, LLC effective June 1, 2024.
- The Company will pay Monomoy $35,000 per month for Mr. Gaiero's services.
Imunon, Inc. filed an 8-K to furnish its quarterly financial results for the period ended March 31, 2024, and to provide a business update via press release.
📋 Key Facts
- Reporting of Q1 2024 financial results (quarter ended March 31, 2024).
- The filing includes an earnings press release as Exhibit 99.1.
- Company held a conference call on May 13, 2024, to discuss results and business updates.
Imunon, Inc. announced the appointment of Stacy R. Lindborg, Ph.D., as President and Chief Executive Officer, effective May 13, 2024. Dr. Lindborg brings extensive pharmaceutical experience from Biogen and Eli Lilly to lead the company.
📋 Key Facts
- Stacy R. Lindborg, Ph.D., appointed President and CEO effective May 13, 2024.
- Initial base salary of $567,000 with a targeted annual performance bonus of 100% of base salary.
- Sign-on bonus of $200,000 subject to certain conditions.
- Equity compensation includes two tranches of 112,500 stock options each (totaling 225,000 shares), vesting over four years in equal fourths.
- Dr. Lindborg previously served as co-CEO at Brainstorm Cell Therapeutics Inc.
Imunon, Inc. has regained compliance with the Nasdaq minimum bid price requirement after its stock closed at or above $1.00 for 10 consecutive business days. This resolves a previous deficiency notice that threatened the company's listing on the Nasdaq Capital Market.
🚩 Red Flags
- Previous history of delisting risk due to sub-$1.00 stock price (implied by the compliance notice).
📋 Key Facts
- Received written notice from Nasdaq on April 10, 2024, confirming compliance with Nasdaq Listing Rule 5550(a)(2).
- Compliance was achieved by meeting or exceeding a $1.00 minimum bid price for 10 consecutive business days.
- The company issued a press release on April 11, 2024, announcing the resolution of the deficiency notice.
Imunon, Inc. filed an 8-K to furnish its press release regarding the financial results for the fiscal year ended December 31, 2023, and a business update.
📋 Key Facts
- Reporting of full-year 2023 financial results as of March 28, 2024.
- The filing includes an announcement regarding a conference call held on March 28, 2024, to discuss business updates and financials.
- Information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 of the Exchange Act.
Imunon, Inc. has amended its bylaws to align with recent changes in the Delaware General Corporation Law (DGCL). The amendments primarily focus on voting thresholds and adjournment procedures for stockholder meetings.
📋 Key Facts
- Board of Directors approved and adopted Amended and Restated Bylaws effective March 15, 2024.
- Amendments revise voting thresholds required for stockholder approval of certain matters.
- Amendments modify provisions relating to adjournment procedures for stockholder meetings to reflect DGCL updates.
Imunon, Inc. announced the resignation of its President and Chief Executive Officer, Dr. Corinne Le Goff, effective March 15, 2024. The company has appointed Executive Chairman Michael H. Tardugno to assume day-to-day leadership during the search for a successor.
🚩 Red Flags
- Sudden departure of the top executive (CEO) in a micro-cap biotech environment often introduces operational uncertainty.
- Leadership transition period creates potential for strategic shifts or execution delays.
📋 Key Facts
- Dr. Corinne Le Goff resigned as President and CEO and from the Board of Directors.
- Resignation is effective March 15, 2024.
- The company states the resignation was not due to any disagreement regarding operations, policies, or practices.
- Executive Chairman Michael H. Tardugno will assume day-to-day leadership and continue directing strategy.
- A search for a new CEO is currently underway.